Psychedelicnewsbreaks Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100 March 17, 2026 depression ONLY AVAILABLE IN PAID PLANS. Originally reported by menafn. Read more Source: https://menafn.com/1110867956/Psychedelicnewsbreaks-Nrx-Pharmaceuticals-Inc-NASDAQ-NRXP-Receives-FDA-Guidance-Supporting-NDA-Review-For-NRX-100
